Aiolos Bio
is a Massachusetts-based clinical-stage biopharmaceutical company that researches and develops novel therapeutics for respiratory and inflammatory diseases... Read moreAiolos Bio
is a Massachusetts-based clinical-stage biopharmaceutical company that researches and develops novel therapeutics for respiratory and inflammatory diseases... Read more
News
Feb 19, 2024
Indian Pharma Post
Aiolos Bio: GSK completes acquisition of Aiolos Bio
Feb 16, 2024
Pharamceutical Technology
Aiolos Bio: GSK concludes Aiolos Bio acquisition for $1.4bn
Feb 15, 2024
City A.M.
Aiolos Bio: GSK snaps up potential asthma treatment gamechanger in 800m deal
Feb 02, 2024
Post Online Media
Aiolos Bio: GSK to acquire Aiolos Bio for up to $1.4 billion
Jan 16, 2024
Outsourcing-Pharma
Aiolos Bio: GSK to pump 200 million into UK to boost medicine production and buys Aiolos Bio for $1.1 billion
Jan 16, 2024
PMLiVE
Aiolos Bio: GSK to expand respiratory pipeline with $1.4bn Aiolos Bio acquisition
Jan 11, 2024
ChinaBio Today
Aiolos Bio: GSK Pays $1.4 Billion to Acquire Aiolos, which In-Licensed a Hengrui Asthma Candidate
Jan 10, 2024
BioCentury
Aiolos Bio: Aiolos team, VCs steer asthma start-up into quick $1B sale to GSK
Jan 10, 2024
Zacks
Aiolos Bio: GSK to Buy Private Biotech, Strengthen Respiratory Pipeline
Jan 10, 2024
Medthority
Aiolos Bio: GSK acquires Aiolos Bio and with it AIO 001, a long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
